Abstract:BackgroundThe majority of patients with acute myelogenous leukemia (AML) still die of their disease. In order to improve survival rates in AML patients, new strategies are necessary to discover biomarkers for the detection and targeted therapy of AML. One of the advantages of the aptamer-based technology is the unique cell-based selection process, which allows us to efficiently select for cell-specific aptamers without knowing which target molecules are present on the cell surface.MethodsThe NB4 AML cell line was used as the target cell population for selecting single stranded DNA aptamers. After determining the affinity of selected aptamers to leukocytes, the aptamers were used to phenotype human bone marrow leukocytes and AML cells in clinical specimens. Then a biotin-labelled aptamer was used to enrich and identify its target surface protein.ResultsThree new aptamers were characterized from the selected aptamer pools (JH6, JH19, and K19). All of them can selectively recognize myeloid cells with Kd in the low nanomole range (2.77 to 12.37 nM). The target of the biotin-labelled K19 aptamer probe was identified as Siglec-5, a surface membrane protein in low abundance whose expression can serve as a biomarker of granulocytic maturation and be used to phenotype AML. More importantly, Siglec-5 expression can be used to detect low concentrations of AML cells in human bone marrow specimens, and functions as a potential target for leukemic therapy.ConclusionsWe have demonstrated a pipeline approach for developing single stranded DNA aptamer probes, phenotyping AML cells in clinical specimens, and then identifying the aptamer-recognized target protein. The developed aptamer probes and identified Siglec-5 protein may potentially be used for leukemic cell detection and therapy in our future clinical practice.

A Dual‐Targeting Circular Aptamer Strategy Enables the Recognition of Different Leukemia Cells with Enhanced Binding Ability

Rapid Identification Of Specific Dna Aptamers Precisely Targeting Cd33 Positive Leukemia Cells Through A Paired Cell-Based Approach

The architecture and biological function of dual antibody-coated dendrimers: enhanced control of circulating tumor cells and their hetero-adhesion to endothelial cells for metastasis prevention.

Molecular recognition of acute myeloid leukemia using aptamers

Aptamers Evolved from Live Cells As Effective Molecular Probes for Cancer Study

Aptamer-Conjugated Nanoparticles for Selective Collection and Detection of Cancer Cells

Cell-specific aptamer probes for membrane protein elucidation in cancer cells.

Aptamer-conjugated Nanomaterials for Specific Cancer Cell Recognition and Targeted Cancer Therapy.

Engineering Circular Aptamer Assemblies with Tunable Selectivity to Cell Membrane Antigens in Vitro and in Vivo.

Dna Aptamer As Molecular Recognition Probe To Selectively Differentiate Tumor Cells

Cancer cell targeting using multiple aptamers conjugated on nanorods.

Nanoparticle-aptamer conjugates for cancer cell targeting and detection.

Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy

Aptamers: Versatile Molecular Recognition Probes for Cancer Detection.

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Molecular Engineering‐Based Aptamer–Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy

Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery

Cell-SELEX-based Aptamer-Conjugated Nanomaterials for Enhanced Targeting of Cancer Cells

Aptamer-based Cell Recognition and Detection

Using Aptamer–Nanoparticle Conjugates for Cancer Cells Detection

Engineering Biomimetic Biosensor Using Dual-Targeting Multivalent Aptamer Regulated 3D DNA Walker Enables High-Performance Detection of Heterogeneous Circulating Tumor Cells.